[{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT6555","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT6555","moa":"FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu","moa":"||Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Belgian Nuclear Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Belgian Nuclear Research Center"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Public Offering","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Public Offering","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Series A Financing","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"PNT2001","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Ionetix"}]
Find Clinical Drug Pipeline Developments & Deals by Point Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
